Full-Time
Confirmed live in the last 24 hours
Develops treatments for eye care diseases
$107.2k - $150.2kAnnually
Senior, Expert
Irvine, CA, USA
Hybrid work model available; some travel may be required.
You match the following Tarsus Pharamceuticals's candidate preferences
Employers are more likely to interview you if you match these preferences:
Tarsus Pharmaceuticals develops treatments for diseases that lack effective solutions, focusing mainly on eye care and infectious diseases. Their key product, XDEMVY, is an FDA-approved eye drop solution for treating Demodex Blepharitis, a condition affecting the eyelids. The company also has a pipeline of potential treatments for Lyme Disease Prevention, Meibomian Gland Disease, and Rosacea. Tarsus differentiates itself from competitors by concentrating on specific medical needs and maintaining a strong commitment to ethical practices and compliance. Their goal is to provide effective treatments for patients suffering from these conditions while expanding their product offerings through research and strategic partnerships.
Company Size
201-500
Company Stage
IPO
Total Funding
$58.4M
Headquarters
Irvine, California
Founded
2017
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Hybrid Work Options
Professional Development Budget
Mutual of America Capital Management LLC invests $4.29 million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS).
Tarsus welcomes Kate Goodrich, M.D., MHS, to its Board of Directors.
IRVINE, Calif.- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a company that applies proven science and new technology to eyecare to improve treatment for patients, has announced the appointment of Elizabeth Yeu, MD, as chief medical officer, effective November 4, 2024.
Meanwhile, Tarsus in April picked up $200 million in financing from Pharmakon Advisors, on top of the $180 million equity offering the company pulled off earlier in the year.
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) - Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP.